Bastiaens Leo
Family Services of Western Pennsylvania, University of Pittsburgh, 33 Sunnyhill Drive, Pittsburgh, PA 15228, USA.
Psychiatr Q. 2008 Jun;79(2):133-7. doi: 10.1007/s11126-008-9070-6. Epub 2008 Mar 8.
To evaluate change in quality of life in a community clinic ADHD population treated with atomoxetine or stimulants. No direct comparisons between atomoxetine and stimulants to improve quality of life in ADHD are available.
A prospective, nonrandomized comparison between ADHD patients treated with atomoxetine or stimulants in one clinic. Structured diagnostic assessment tools and a specific quality of life measure were used.
84 patients (atomoxetine n = 39/stimulants n = 45), between the ages of 5 and 18, were treated for approximately 8 months. At end point, there were no significant differences in improvements of quality of life between the two groups. Age, participation in psychotherapy, and parental disability were not correlated with quality of life changes. Patients with lower baseline scores improved most.
Both atomoxetine and stimulants led to a modest increase in quality of life in this community clinic ADHD population.
评估在社区诊所中接受托莫西汀或兴奋剂治疗的多动症患者的生活质量变化。目前尚无关于托莫西汀与兴奋剂在改善多动症患者生活质量方面的直接比较。
在一家诊所对接受托莫西汀或兴奋剂治疗的多动症患者进行前瞻性、非随机比较。使用了结构化诊断评估工具和特定的生活质量测量方法。
84名年龄在5至18岁之间的患者（托莫西汀组n = 39/兴奋剂组n = 45）接受了约8个月的治疗。在终点时，两组在生活质量改善方面无显著差异。年龄、参与心理治疗以及父母残疾状况与生活质量变化无关。基线分数较低的患者改善最为明显。
在这个社区诊所的多动症患者群体中，托莫西汀和兴奋剂均使生活质量有适度提高。
